In October 2017, MAPS raised $404,110 in new donations and pledges from 543 supporters. In the same month, MAPS hosted two fundraising events, one in New York City and one in Atlanta. Together, both events raised over $100,000.
In January 2018, MAPS will travel to Colorado to host Legalizing Psychedelic Medicines events near our study sites in Boulder and Fort Collins. We are still finalizing details, though we expect to be in Colorado sometime around January 25-28.
As MAPS shifts focus to beginning its Phase 3 studies of MDMA-assisted psychotherapy for PTSD, we face a fundraising challenge. In August, MAPS was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). This encouraging news demonstrates the FDA’s support and desire to expeditiously make MDMA into a legal medicine. Phase 3 studies will cost between $26-$36 million for both FDA and European Medicines Agency (EMA) approval. With $15.5 million in hand or in multi-year pledges, there’s still a funding gap we need to close.
We extend a special thanks to those who so generously supported MAPS last month:
General Support
- Anonymous ($175,000)
- Fire Monkey Fund ($100,000)
- Maeve Rockefeller ($10,000)
- Anonymous ($5,000)
- Ryan Crane ($2,500)
- Chris Freund ($1,618)
- SpinCycle ($1,100)
MDMA/PTSD Phase 3 Studies
- Laura & Ed Littlefield ($40,000)
- Rodrigo Nino ($20,000)
- Anonymous ($5,000)
- Robert Eisenberg ($2,000)
- Clifford Perlman ($1,000)
MDMA/PTSD Phase 2 Study in Vancouver, BC
- Normand Boivin ($2,500)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate
Learn how to include MAPS in your will or estate plans.
Learn more about hosting a Global Psychedelic Dinner to fundraise for MAPS.
